Obesity is a major global health problem, increasing the risk of many serious diseases like heart disease, diabetes, and some types of cancer.
Despite its widespread impact, there are currently no pills that effectively treat severe obesity. This lack of treatment options makes it even more challenging for those struggling with obesity to manage their condition.
However, recent research from Johns Hopkins Medicine might offer a new hope. Scientists have been studying a drug that was originally developed to treat conditions like Alzheimer’s disease, schizophrenia, and sickle cell disease.
This drug targets an enzyme in the body called PDE9. The research found that this drug not only helped reduce obesity and fatty liver in mice but also improved heart function—all without requiring the mice to change their diet or exercise routines.
This new discovery builds on earlier research from the same team. Back in 2015, they found that the PDE9 enzyme is active in the heart and can worsen heart disease, especially when someone has high blood pressure.
The idea that blocking this enzyme could help with heart disease led them to wonder if it could also have other health benefits.
PDE9 inhibitors, the type of drug used in this study, are still in the experimental phase. This means they’re not yet available as a treatment option for the public.
These inhibitors work similarly to drugs like Viagra, which blocks a related enzyme called PDE5. Both of these enzymes control a substance in the body called cyclic GMP, which plays a role in various bodily functions.
In the study with mice, the researchers explored whether blocking PDE9 could lead to broader health improvements.
They looked at whether it could help lower high blood pressure, reduce high blood sugar levels, decrease cholesterol and triglycerides, and reduce excess body fat, especially around the waist.
The specific drug they used in the study, known as PF-04447943, was originally developed by Pfizer Inc. to treat Alzheimer’s disease.
Although the drug was not successful in treating Alzheimer’s, it was found to be safe in clinical trials with more than 100 people, who did not experience any serious side effects.
Given the fact that over 40% of U.S. residents are considered obese, according to the Centers for Disease Control and Prevention (CDC), the implications of this research could be significant. Particularly, the CDC reports that 43% of American women over 60 are obese.
If the effects observed in mice can be replicated in humans, it might mean that a person weighing 250 pounds could potentially lose about 50 pounds using an oral PDE9 inhibitor, all without changing their eating or exercise habits.
This study, led by David Kass and published in the Journal of Clinical Investigation, opens up new possibilities for managing obesity. It hints at a future where managing weight could become easier and more accessible, without the need for drastic lifestyle changes.
This is particularly important given the ongoing debate about the causes of obesity, challenging the idea that overeating is the sole driver of weight gain.
However, it’s important to note that more research is needed to confirm these findings in humans. Scientists need to make sure that PDE9 inhibitors are both safe and effective when used as a treatment for obesity and related metabolic conditions in people.
If successful, this research could lead to a groundbreaking treatment for obesity, offering new hope to millions of people around the world who struggle with their weight.
If you care about liver health, please read studies about simple habit that could give you a healthy liver, and common diabetes drug that may reverse liver inflammation.
For more information about health, please see recent studies about simple blood test that could detect your risk of fatty liver disease, and results showing this green diet may strongly lower non-alcoholic fatty liver disease.
Copyright © 2024 Knowridge Science Report. All rights reserved.
